Cellular activity varies with model and assay. Asiatic acid inhibited the 48 h XTT growth readout in breast-cancer cells, while a separate A549 NF-κB reporter assay reported IC50 >20 µM. Synthetic asiatic-acid derivatives in the latter paper were evaluated separately and their binding results should not be attributed to the parent compound. [1,2]
Growth inhibition in breast-cancer cells
Cell-based study · Human MCF-7 and MDA-MB-231 breast-cancer cells [1]
Asiatic acid reduced the XTT proliferation readout after 48 h. The reported IC50 was lower in MCF-7 than in MDA-MB-231 cells.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0, 2.5, 5, 10 and 20 µM
- Exposure duration
- 48 h
- Method
- Cell exposure followed by XTT measurement
- Vehicle
- Solvent control; DMSO identified elsewhere in the same manuscript, but its final concentration in the XTT assay is not specified.
- Co-treatment
- Asiatic acid alone
- Reported limits
- No IC50 uncertainty estimate reported; final solvent percentage not specified. Figure 1 legend reports three determinations, mean ± SD for plotted values.
Methods and source locations
Compound reported in the paper: Asiatic acid; Compound label in the paper: Asiatic acid
Literature results for asiatic acid in the specified cell models; no Adooq lot validation or recommended concentration.
Manuscript pp. 9–10 and 15; Figure 1A (p. 42), legend p. 37
MCF-7 cell-growth inhibition: XTT assay — Manuscript p. 10, Cell proliferation assay; p. 15, first Results paragraph; Figure 1A and legend p. 37
MDA-MB-231 cell-growth inhibition: XTT assay — Manuscript p. 10, Cell proliferation assay; p. 15, first Results paragraph; Figure 1A and legend p. 37
p38 and ERK pathway involvement in cell-cycle arrest and apoptosis
Cell-based study · Human MCF-7 and MDA-MB-231 breast-cancer cells [1]
Asiatic acid increased p38 and ERK1/2 phosphorylation without comparable JNK activation. Pharmacological inhibition and siRNA experiments supported p38 involvement in S–G2/M accumulation and ERK involvement in apoptosis. U0126 reduced apoptosis without significantly reversing S–G2/M accumulation; SB203580 delayed rather than abolished apoptosis.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 µM asiatic acid; inhibitor arms used 20 µM SB203580 or U0126
- Exposure duration
- Phosphorylation: 1, 3, 6 and 12 h; inhibitor pretreatment: 1 h; cell-cycle readout: 12 h; apoptosis readouts: 24 and 48 h
- Method
- Cellular exposure with matched controls, pharmacological inhibition and siRNA perturbation
- Vehicle
- Equal-volume DMSO control for Figure 4; final percentage not specified.
- Co-treatment
- Separate SB203580 or U0126 co-treatment arms and separate p38 or ERK2 siRNA arms; not a combined therapeutic regimen.
- Reported limits
- Final DMSO percentage and siRNA concentration not specified in the selected manuscript methods. Numeric fold changes were not inferred from blots or bars.
Methods and source locations
Compound reported in the paper: Asiatic acid; Compound label in the paper: Asiatic acid
Literature results for asiatic acid in the specified cell models; no Adooq lot validation or recommended concentration.
Manuscript pp. 9, 11–14, 19–23; Figures 4, 5 and 8; legends pp. 39–41
p38 and ERK1/2 activation; JNK comparison: Immunoblotting and cellular kinase-activity assays — Manuscript pp. 19–20; Figure 4A–B (p. 45), legend p. 39
Dependence of cell-cycle and apoptotic responses on p38 and ERK signaling: Flow cytometry and nucleosome ELISA with chemical inhibitors; p38/ERK2 siRNA corroboration — Manuscript pp. 20–23; Figures 5B–D and 8C,E (pp. 46,49); legends pp. 39–41
Limited inhibition in an NF-κB reporter assay
Cell-based study · Human A549 cells with an NF-κB luciferase reporter, stimulated with TNF-α [2]
Parent asiatic acid had a reported NF-κB reporter IC50 >20 µM. The high-affinity binding and stronger activity reported for derivative 6k do not describe asiatic acid.
Literature-Reported Treatment Conditions
- Exposure duration
- 7 h co-treatment
- Method
- Reporter assay with TNF-α (15 ng/mL); TNF-α-only and unstimulated controls; IMD-0354 reference inhibitor
- Vehicle
- Not specified in the reporter methods.
- Co-treatment
- TNF-α stimulation; no anticancer-drug combination.
- Reported limits
- Exact AA test-concentration series and vehicle not specified. The >20 µM result is a potency bound, not a dosing instruction.
Methods and source locations
Compound reported in the paper: Asiatic acid; Compound label in the paper: AA (compound 1)
Literature results for asiatic acid in the specified cell models; no Adooq lot validation or recommended concentration.
Table 1, AA row and footnote; NF-κB reporter Results and Experimental methods; General; Scheme 1
Inhibition of TNF-α-induced NF-κB transcriptional activity: Bright-Glo luciferase reporter assay; signal corrected for background and cell viability — Table 1, AA row; Experimental methods, In vitro inhibition of TNF-a-induced NF-κB activation in A549 lung cells
Cytotoxicity across a cell-line panel
Cell-based study · T24, HepG2, A549, NCI-H460 and HL-7702 cells [2]
The 48 h MTT panel reported asiatic acid IC50 values of 35.37–44.82 µM in four tumor cell lines and >50 µM in HL-7702. The reported ± terms have an ambiguous statistical definition in the paper.
Literature-Reported Treatment Conditions
- Exposure duration
- 48 h exposure
- Method
- MTT viability assay; doxorubicin reference comparator
- Vehicle
- Treatment vehicle not specified; DMSO used during MTT processing must not be assumed to be the dosing vehicle.
- Co-treatment
- Asiatic acid alone; doxorubicin was a separate comparator.
- Reported limits
- Exact AA concentration series and treatment vehicle not specified. Table footnote says mean ± SD but defines SD as standard error of the mean; dispersion type remains unresolved.
Methods and source locations
Compound reported in the paper: Asiatic acid; Compound label in the paper: AA (compound 1)
Literature results for asiatic acid in the specified cell models; no Adooq lot validation or recommended concentration.
Table 2, AA row and footnotes; Experimental methods, Cytotoxicity assay; General; Scheme 1
T24 viability reduction: MTT assay — Table 2, AA row, T24 column and footnote a; Experimental methods, Cytotoxicity assay
HepG2 viability reduction: MTT assay — Table 2, AA row, HepG2 column and footnote a; Experimental methods, Cytotoxicity assay
A549 viability reduction: MTT assay — Table 2, AA row, A549 column and footnote a; Experimental methods, Cytotoxicity assay
NCI-H460 viability reduction: MTT assay — Table 2, AA row, NCI-H460 column and footnote a; Experimental methods, Cytotoxicity assay
HL-7702 viability reduction: MTT assay — Table 2, AA row, HL-7702 column and footnote a; Experimental methods, Cytotoxicity assay